Connect your AI

AnaptysBio, Inc. ANAB Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

Eli LillyLLY

$161M+4.5%

PfizerPFE

$272M+60.0%

AmgenAMGN

$75M-11.8%

Regeneron PharmaceuticalsREGN

$257.4M+0.7%

BiogenBIIB

$84M+3.7%

Other financials

Income statement

Revenue$25.6M-8.0%

Operating income-$34.6M-25.8%

Net income-$52.9M-34.5%

EPS (diluted)-$1.84-43.8%

Balance sheet

Cash & equivalents$248.5M+152%

Total debt$13.6K-99.9%

Total equity$12.7M-62.5%

Total assets$329.7M-21.9%

Cash flow

Operating cash flow-$25.9M-142%

CapEx$17.0K-51.4%

Free cash flow-$25.9M-142%

Valuation

Market cap$1.73B+180%

Enterprise value$1.48B+176%

P/S7.4×+1.9×

Profitability

Operating margin17.6%+9.6pp

Net margin-49.9%-22.6pp

FCF margin1.9%+1.0pp

Returns & leverage

Return on equity-343.8%-1,012pp

Debt / equity0×-0.5×

Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AnaptysBio, Inc.'s stock-based comp?: AnaptysBio, Inc. (ANAB) reported stock-based comp of $14.22M in Q1 2026.
How has AnaptysBio, Inc.'s stock-based comp changed year-over-year?: AnaptysBio, Inc.'s stock-based comp increased by 55.0% year-over-year, from $9.17M to $14.22M.
What is the long-term trend for AnaptysBio, Inc.'s stock-based comp?: Over 4 years (2021 to 2025), AnaptysBio, Inc.'s stock-based comp has grown at a 23.8% compound annual growth rate (CAGR), from $15.35M to $36.07M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.